They might be riding off to prison together — instead of "into the sunset together."

Federal prosecutors in New York on Thursday charged a former top executive at big drugmaker Valeant Pharmaceuticals and the ex-CEO of the specialty pharmacy Philidor Rx Services in a multimillion-dollar fraud and kickback scheme.

A criminal complaint accuses Phildor's former CEO Andrew Davenport of secretly paying Valeant exec Gary Tanner about $10 million in kickbacks to steer Valeant's business to and potentially acquire Philidor, where Davenport was the biggest shareholder.

The complaint said Tanner, who ended up being vice president of Valeant's "Access Solutions Team," helped "advance Davenport's interests" by having Valeant pay Davenport personally "over $40 million, and potentially tens of millions of additional dollars" in connection with an option to buy Philidor that Valeant purchased.

"They had in effect illegally converted Valeant shareholders' money into their own personal nest eggs," Manhattan U.S. Attorney Preet Bharara said at a Thursday afternoon news conference.

Prosecutors accuse Tanner of promoting Philidor to Valeant's leadership, and resisting efforts to reduce Valeant's dependency on Philidor, which ultimately led to Valeant negotiating an option to buy the specialty pharmacy.